Novel CAR-T Cell Therapy Studied for its Effectiveness in the Treatment of Prostate Cancer

Release Date: 05-Nov-2020

For the treatment of the patients suffering from metastatic castration-resistant prostate cancer (mCRPC), CART-PSMA-TGFandbeta;Rd as adoptive chimeric antigen receptor (CAR) T-cell therapy is estimated to be safe as well as feasible when combined with lymphodepleting (LD) chemotherapy. The study that was conducted to test the efficacy of CAR-T cell therapy for the treatment of patients suffering from metastatic castration-resistant prostate cancer (mCRPC) is the first-in-human investigation. Three different dose cohorts were selected for the study.

The total number of patients that were enrolled in the respective study were 10 and all the patients were infused with CAR-T cell therapy products. Some of the metastatic sites that were observed in the patients enrolled in the study were: lymphoma node, bone and bladder. Also, the patients enrolled in the respective study showed some side effects such as anemia, disseminated intravascular coagulation, acute kidney injury, sepsis, and CRS. Peripheral blood test was done to analyze the tumor response in the patients post injection of CAR-T cell product.

It was found that inflammatory cytokines were expressed in the blood as well as lymphodepleting chemotherapy enhancement in peripheral blood CAR T-cell expansion. According to the researchers involved in the respective clinical research study, adoptive CAR-T cell therapy can get classified as a novel strategy for the treatment of prostate cancer as it is capable of enhancing the immune response in the patients. Although the first few studies were conducted in invivo models, therefore, researchers are now focused towards taking the study forward in the humans.